Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NTRP Neurotrope (NTRP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesShort InterestTrends About Neurotrope Stock (NASDAQ:NTRP) 30 days 90 days 365 days Advanced Chart Ad Golden CrestIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.Click Here For Your Free Guide Get Neurotrope alerts:Sign Up Key Stats Today's Range$1.80▼$1.9550-Day Range$0.92▼$1.0552-Week Range$0.68▼$3.85Volume7,838 shsAverage Volume35,220 shsMarket Capitalization$2.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.Read More… Is Your 401(k) Safe? The Real Risk No One Sees Coming (Ad)Every day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.Click Here For Your Free Guide Neurotrope Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks6th Percentile Overall ScoreNTRP MarketRank™: Neurotrope scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Neurotrope. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neurotrope are expected to grow in the coming year, from ($0.91) to ($0.10) per share.Price to Book Value per Share RatioNeurotrope has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neurotrope's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.91% of the float of Neurotrope has been sold short.Short Interest Ratio / Days to CoverNeurotrope has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurotrope has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurotrope does not currently pay a dividend.Dividend GrowthNeurotrope does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.91% of the float of Neurotrope has been sold short.Short Interest Ratio / Days to CoverNeurotrope has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurotrope has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Neurotrope this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neurotrope insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.70% of the stock of Neurotrope is held by insiders.Percentage Held by InstitutionsOnly 3.81% of the stock of Neurotrope is held by institutions.Read more about Neurotrope's insider trading history. Receive NTRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurotrope and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRP Stock News HeadlinesNextTrip (NASDAQ:NTRP) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comNextTrip, Inc.: NextTrip Introduces Group Booking Technology Platform to Streamline and Simplify Travel for GroupsAugust 2, 2024 | finanznachrichten.deIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.November 14, 2024 | Golden Crest (Ad)NextTrip, Inc. (NTRP) Stock Price, News, Quote & History - Yahoo FinanceMay 18, 2024 | finance.yahoo.comNextTrip, Inc. (NTRP) Latest Stock News & Headlines - Yahoo FinanceApril 30, 2024 | finance.yahoo.comNextTrip Inc NTRPApril 4, 2024 | morningstar.comAlzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsightAugust 17, 2023 | finance.yahoo.comAt 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research - Yahoo FinanceJune 22, 2022 | finance.yahoo.comSee More Headlines NTRP Stock Analysis - Frequently Asked Questions How were Neurotrope's earnings last quarter? Neurotrope, Inc. (NASDAQ:NTRP) issued its quarterly earnings data on Tuesday, October, 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05. What other stocks do shareholders of Neurotrope own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Bristol-Myers Squibb (BMY), Intel (INTC), Meta Platforms (META) and Pfizer (PFE). Company Calendar Last Earnings10/30/2018Today11/13/2024Next Earnings (Estimated)1/21/2025Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry Transportation services Sub-IndustryN/A Current SymbolNASDAQ:NTRP CUSIPN/A CIK1513856 Webwww.neurotropebioscience.com Phone973-242-0005Fax505-424-3174Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax Margin-904.14% Return on Equity-286.56% Return on Assets-100.34% Debt Debt-to-Equity RatioN/A Current Ratio0.27 Quick Ratio0.27 Sales & Book Value Annual Sales$630,000.00 Price / Sales4.19 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book0.56Miscellaneous Outstanding Shares1,420,000Free Float1,283,000Market Cap$2.64 million OptionableNo Data Beta1.67 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:NTRP) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhat are you hiding Elon?? (Tesla’s secret 69% dividend)Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurotrope, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurotrope With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.